One-step HCV RNA Testing Among SSP Participants (HOT Study)
NCT ID: NCT06634342
Last Updated: 2024-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
227 participants
INTERVENTIONAL
2024-11-30
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1\. How will point-of-care HCV RNA testing with Xpert, provided at an SSP, effect how people who use drugs receive their results, get linked to HCV care services, and initiate and complete HCV treatment\> Aim 2: What are the most effective ways to implement point of care HCV RNA testing in syringe services programs?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improving Perinatal Outcomes Among Kenyan Pregnant Women With an Integrated STI Testing Model
NCT06203951
Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED
NCT01989130
Screening for Hepatitis C During Pregnancy at a Toronto Inner City Prenatal Clinic
NCT00348660
Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.
NCT01540227
Evaluation of the Diagnostic Sensitivity and Specificity of the Determine™ Syphilis Advanced Test.
NCT06584214
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
HCV testing and linkage to care activities will be monitored for six months as part of this study. Once all training and protocol development is complete, the PHSKC SSP will make the one-step HCV testing algorithm available to their clients and invite them to participate. SSP staff will conduct the one-step HCV testing and linkage algorithm according to the project protocol.
Clients who choose to be tested will participate in an informed consent process for study procedures. Participants who complete the HCV test and receive their results will receive a $15 incentive. All quantitative data related to the study will be entered directly into REDCap data collection tools. SSP staff who conduct testing will record a participant's HCV test result, whether/when they received their result, and whether/when they received a referral to HCV care. Participants will need to provide identifying information (e.g., name and birthdate) and sign a release of information form to facilitate longitudinal data collection on linkage to care and treatment initiation. SSP staff will use this information to follow up with providers to indicate whether/when participants attended an HCV care visit, whether/when participants began HCV treatment, and if they achieved cure (i.e., sustained viral response at 4 weeks). No other information will be requested or recorded from health care providers.
We will ask the PHSKC SSP to gather data on prior HCV testing and linkage efforts for the 6 months prior to the implementation of the one-step algorithm (standard of care). This will include any data that are available related to volume of HCV screening and RNA testing, participant receipt of results, and linkage to care efforts.
During the six months of the testing project, we will also conduct qualitative data collection. First, UW staff will conduct 12 in-depth interviews with participants who were involved in the testing component of the study. These interviews will be conducted with participants who received negative HCV RNA results, both those who were and were not linked to care, and those who started HCV treatment. The goal of these interviews will be to understand the participants' previous testing experiences and interest in HCV care, present testing experiences and interest in care, and overall impressions of the one-step testing algorithm. Staff will use purposive sampling to recruit participants and conduct private interviews using a semi-structured interview guide. Participants who complete these interviews will receive a $40 incentive.
Second, UW staff will conduct in-depth interviews with all staff at the PHSKC SSP who were involved with the HCV testing study to understand the experiences of staff who conducted the one-step testing algorithm compared to previous testing algorithms (e.g., HCV rapid screening and/or laboratory-based HCV RNA testing). Specific questions will assess facilitators and barriers to providing one-step HCV testing in SSPs, as well as recommendations for implementing similar protocols in other SSPs.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants of a syringe services program
Participants of the syringe services program who will be offered point-of-care hepatitis C RNA testing will be adults 22 or older who do not already know they have HCV infection.
HCV RNA Rapid testing
Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HCV RNA Rapid testing
Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* past participation in this study.
22 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Washington
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sara Glick
Associate Professor: Medicine- Allergy and Infectious Disease
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sara Glick, PhD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of Washington
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00021203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.